Processa Pharmaceuticals Announces First Patient Enrolled in the PCS12852 Phase IIA Trial for the Treatment of Gastroparesis

Processa Pharmaceuticals, Inc., announced that it has enrolled its first patient in the Phase IIA clinical trial of PCS12852 in patients with moderate to severe gastroparesis.